Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A11 | Q9UPY5 | 16/20 | 0.88 |
| ▸ | VDAC2 | P45880 | 1/20 | 0.88 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4463410 | 0.94 | SLC7A11 (0.84) | SLC7A11VDAC2LMNAMAPK1KDM4E | |
| Erastin SCHEMBL4457820 | 0.94 | SLC7A11 (1.00) | SLC7A11VDAC2LMNAMAPK1HIF1A | |
| Erastin SCHEMBL22213543 | 0.94 | SLC7A11 (1.00) | SLC7A11VDAC2LMNAMAPK1HIF1A | |
| Erastin SCHEMBL29370998 | 0.94 | SLC7A11 (1.00) | SLC7A11VDAC2LMNAMAPK1HIF1A | |
| Erastin SCHEMBL31385520 | 0.94 | SLC7A11 (1.00) | SLC7A11VDAC2LMNAMAPK1HIF1A | |
| SCHEMBL14010407 | 0.93 | SLC7A11 (0.81) | SLC7A11VDAC2LMNAMAPK1KDM4E | |
| SCHEMBL4459138 | 0.92 | SLC7A11 (0.80) | SLC7A11VDAC2LMNAMAPK1KDM4E | |
| SCHEMBL4452788 | 0.92 | SLC7A11 (0.79) | SLC7A11VDAC2LMNAMAPK1KDM4E | |
| SCHEMBL4519119 | 0.89 | SLC7A11 (0.85) | SLC7A11VDAC2LMNAMAPK1HIF1A | |
| SCHEMBL14010414 | 0.89 | SLC7A11 (0.81) | SLC7A11VDAC2LMNAMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160271133-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | PROLEXYS PHARMACEUTICALS INC (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160271133-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | PROLEXYS PHARMACEUTICALS INC (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160015710-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | PROLEXYS PHARMACEUTICALS INC (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160015710-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | PROLEXYS PHARMACEUTICALS INC (US) | 2016-01-21 | — | — | US | disclosed |
| US-20140227221-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | PROLEXYS PHARMACEUTICALS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140227221-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | PROLEXYS PHARMACEUTICALS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8575143-B2 | 3-aryl-substituted quinazolones, and uses thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575143-B2 | 3-aryl-substituted quinazolones, and uses thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575143-B2 | 3-aryl-substituted quinazolones, and uses thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110123486-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | PROLEXYS PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110123486-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | PROLEXYS PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110092489-A1 | 3-Aryl-Substituted Quinazolones, and Uses Thereof | Prolexys Pharmaceuticals ,Inc. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092489-A1 | 3-Aryl-Substituted Quinazolones, and Uses Thereof | Prolexys Pharmaceuticals ,Inc. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092489-A1 | 3-Aryl-Substituted Quinazolones, and Uses Thereof | Prolexys Pharmaceuticals ,Inc. (US) | 2011-04-21 | — | — | US | disclosed |
| WO-2009002553-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | PROLEXYS PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2007076087-A2 | 3-ARYL-SUBSTITUTED QUINAZOLONES, AND USES THEREOF | PROLEXYS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271133-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | MCL1, SLC11A2, MEN1 | SLC7A11 453/4885VDAC2 3099/4885LMNA 1737/4885 |
| US-20110092489-A1 | 3-Aryl-Substituted Quinazolones, and Uses Thereof | MKI67, MCL1, HCCS | SLC7A11 3069/4885VDAC2 3317/4885LMNA 1964/4885 |
| US-20140227221-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | MCL1, BCL3, DDIT3 | SLC7A11 1278/4885VDAC2 4580/4885LMNA 1726/4885 |
| US-20160015710-A1 | Methods of Treating Multiple Myeloma and Resistant Cancers | MCL1, SLC11A2, MEN1 | SLC7A11 453/4885VDAC2 3099/4885LMNA 1737/4885 |
| US-20110123486-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | MCL1, BCL3, DDIT3 | SLC7A11 1278/4885VDAC2 4580/4885LMNA 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.